{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:05:05Z","timestamp":1790546705619,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astra-Zeneca, France"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes. The objective was to estimate the incidence of the first occurring CVRD manifestation and cumulative hospitalization costs of each CVRD manifestation for type 2 diabetes without CVRD history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort study of all type 2 diabetes free of CVRD as of January 1st 2014, was identified and followed-up for 5 years within the French SNDS nationwide claims database. The cumulative incidence of the first occurring CVRD manifestation was estimated using the cumulative incidence function, with death as a competing risk. Cumulative hospitalization costs of each CVRD manifestations were estimated from the perspective of all payers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2,079,089 type 2 diabetes without cancer or transplantation, 76.5% were free of CVRD at baseline with a mean age of 65 years, 52% of women and 7% with microvascular complications history. The cumulative incidence of a first CVRD manifestation was 15.3% after 5 years of follow-up with a constant linear increase over time for all CVRD manifestations: The most frequent was CKD representing 40.6% of first occurred CVRD manifestation, followed by HF (23.0%), then PAD (13.5%), stroke (13.2%) and MI (9.7%). HF and CKD together reached about one patient out of ten after 5 years and represented 63.6% of first CVRD manifestations. The 5-year global cost of all CVRD hospitalizations was 3.9\u00a0billion euros (B\u20ac), i.e. 2,450\u20ac per patient of the whole cohort, with an exponential increase over time for each specific CVRD manifestation. The costliest was CKD (2.0 B\u20ac), followed by HF (1.2 B\u20ac), then PAD (0.7 B\u20ac), stroke (0.6 B\u20ac) and MI (0.3 B\u20ac).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>While MI, stroke and PAD remain classic major risks of complications for CVRD-free type 2 diabetes, HF and CKD nowadays represent individually a higher risk and cost than each of these classic manifestations, and jointly represents a risk and a cost twice as high as these three classic manifestations all together. This should encourage the development of specific HF and CKD preventive strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-023-02101-1","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:01:41Z","timestamp":1704801701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4005-7928","authenticated-orcid":false,"given":"Patrick","family":"Blin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-7355","authenticated-orcid":false,"given":"Michael","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5202-6902","authenticated-orcid":false,"given":"Patrick","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-1586","authenticated-orcid":false,"given":"Philippe","family":"Zaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-3288","authenticated-orcid":false,"given":"Estelle","family":"Guiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunia","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-683X","authenticated-orcid":false,"given":"Caroline","family":"Dureau-Pournin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Agn\u00e8s","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6726-6215","authenticated-orcid":false,"given":"R\u00e9gis","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Thomas-Delecourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Bineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-2817","authenticated-orcid":false,"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-1167","authenticated-orcid":false,"given":"C\u00e9cile","family":"Droz-Perroteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"key":"2101_CR1","volume-title":"IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS","author":"DJ Magliano","year":"2021","unstructured":"Magliano DJ, Boyko EJ. IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS. 10th ed. Brussels: International Diabetes Federation; 2021.","edition":"10"},{"key":"2101_CR2","unstructured":"Diabetes. accessed November 4, n.d. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes (Accessed November 4, 2022)."},{"key":"2101_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"S Rao Kondapally Seshasai","year":"2011","unstructured":"Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes Mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1008862.","journal-title":"N Engl J Med"},{"key":"2101_CR4","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/eurheartj\/eht142","volume":"34","author":"JA Beckman","year":"2013","unstructured":"Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular Disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34:2444\u201352. https:\/\/doi.org\/10.1093\/eurheartj\/eht142.","journal-title":"Eur Heart J"},{"key":"2101_CR5","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"ATF Members","year":"2013","unstructured":"Members ATF, Ryd\u00e9n L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC guidelines on diabetes, pre-diabetes, and Cardiovascular Diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035\u201387. https:\/\/doi.org\/10.1093\/eurheartj\/eht108.","journal-title":"Eur Heart J"},{"key":"2101_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E Di Angelantonio","year":"2015","unstructured":"Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, et al. Association of Cardiometabolic Multimorbidity with Mortality. JAMA. 2015;314:52\u201360. https:\/\/doi.org\/10.1001\/jama.2015.7008.","journal-title":"JAMA"},{"key":"2101_CR7","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson A-M, Miftaraj M, et al. Mortality and Cardiovascular Disease in Type 1 and type 2 Diabetes. N Engl J Med. 2017;376:1407\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1608664.","journal-title":"N Engl J Med"},{"key":"2101_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and Cardiovascular Diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323. https:\/\/doi.org\/10.1093\/eurheartj\/ehz486.","journal-title":"Eur Heart J"},{"key":"2101_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12933-021-01416-1","volume":"20","author":"P Blin","year":"2021","unstructured":"Blin P, Darmon P, Henry P, Guiard E, Bernard M-A, Dureau-Pournin C, et al. Patients with stable coronary artery Disease and type 2 Diabetes but without prior Myocardial Infarction or Stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database. Cardiovasc Diabetol. 2021;20:229. https:\/\/doi.org\/10.1186\/s12933-021-01416-1.","journal-title":"Cardiovasc Diabetol"},{"key":"2101_CR10","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 Diabetes. N Engl J Med. 2017;377:644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med"},{"key":"2101_CR11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and Heart Failure in type 2 Diabetes Mellitus: results from the CANVAS Program. Circulation. 2018;138:458\u201368. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034222.","journal-title":"Circulation"},{"key":"2101_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and Cardiovascular outcomes in patients with type 2 Diabetes. N Engl J Med. 2018;379:633\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1800256.","journal-title":"N Engl J Med"},{"key":"2101_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","volume":"140","author":"KW Mahaffey","year":"2019","unstructured":"Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, et al. Canagliflozin and Cardiovascular and renal outcomes in type 2 Diabetes Mellitus and chronic Kidney Disease in primary and secondary Cardiovascular Prevention groups. Circulation. 2019;140:739\u201350. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042007.","journal-title":"Circulation"},{"key":"2101_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular outcomes in type 2 Diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"2101_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of Kidney Disease in patients with type 2 Diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7:606\u201317. https:\/\/doi.org\/10.1016\/S2213-8587(19)30180-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2101_CR16","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, et al. Effect of Dapagliflozin on Heart Failure and mortality in type 2 Diabetes Mellitus. Circulation. 2019;139:2528\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040130.","journal-title":"Circulation"},{"key":"2101_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14074","volume":"22","author":"KI Birkeland","year":"2020","unstructured":"Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart Failure and chronic Kidney Disease manifestation and mortality risk associations in type 2 Diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22:1607\u201318. https:\/\/doi.org\/10.1111\/dom.14074.","journal-title":"Diabetes Obes Metab"},{"key":"2101_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/dom.14189","volume":"23","author":"KI Birkeland","year":"2021","unstructured":"Birkeland KI, Bodegard J, Banerjee A, Kim DJ, Norhammar A, Eriksson JW, et al. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 Diabetes without cardiovascular and renal Diseases: a large multinational observational study. Diabetes Obes Metab. 2021;23:75\u201385. https:\/\/doi.org\/10.1111\/dom.14189.","journal-title":"Diabetes Obes Metab"},{"key":"2101_CR19","doi-asserted-by":"publisher","first-page":"109146","DOI":"10.1016\/j.diabres.2021.109146","volume":"183","author":"Y Kawai","year":"2022","unstructured":"Kawai Y, Uneda K, Yamada T, Kinguchi S, Kobayashi K, Azushima K, et al. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 Diabetes Mellitus patients with\/without albuminuria: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;183:109146. https:\/\/doi.org\/10.1016\/j.diabres.2021.109146.","journal-title":"Diabetes Res Clin Pract"},{"key":"2101_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12916-022-02234-2","volume":"20","author":"R Zhang","year":"2022","unstructured":"Zhang R, Mamza JB, Morris T, Godfrey G, Asselbergs FW, Denaxas S, et al. Lifetime risk of cardiovascular-renal Disease in type 2 Diabetes: a population-based study in 473,399 individuals. BMC Med. 2022;20:63. https:\/\/doi.org\/10.1186\/s12916-022-02234-2.","journal-title":"BMC Med"},{"key":"2101_CR21","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/dom.14698","volume":"24","author":"A Norhammar","year":"2022","unstructured":"Norhammar A, Bodegard J, Eriksson JW, Haller H, Linssen GCM, Banerjee A, et al. Cost of healthcare utilization associated with incident cardiovascular and renal Disease in individuals with type 2 Diabetes: a multinational, observational study across 12 countries. Diabetes Obes Metab. 2022;24:1277\u201387. https:\/\/doi.org\/10.1111\/dom.14698.","journal-title":"Diabetes Obes Metab"},{"key":"2101_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954\u201362. https:\/\/doi.org\/10.1002\/pds.4233.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2101_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Revue d\u2019\u00c9pid\u00e9miologie. et de Sant\u00e9 Publique. 2017;65:149\u201367. https:\/\/doi.org\/10.1016\/j.respe.2017.05.004.","journal-title":"et de Sant\u00e9 Publique"},{"key":"2101_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00038-018-1186-3","volume":"64","author":"S Fuentes","year":"2019","unstructured":"Fuentes S, Cosson E, Mandereau-Bruno L, Fagot-Campagna A, Bernillon P, Goldberg M, et al. Identifying Diabetes cases in health administrative databases: a validation study based on a large French cohort. Int J Public Health. 2019;64:441\u201350. https:\/\/doi.org\/10.1007\/s00038-018-1186-3.","journal-title":"Int J Public Health"},{"key":"2101_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/bcp.12807","volume":"81","author":"P Blin","year":"2016","unstructured":"Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol. 2016;81:569\u201378. https:\/\/doi.org\/10.1111\/bcp.12807.","journal-title":"Br J Clin Pharmacol"},{"key":"2101_CR26","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/bcp.13291","volume":"83","author":"P Blin","year":"2017","unstructured":"Blin P, Dureau-Pournin C, Lassalle R, Jov\u00e9 J, Thomas-Delecourt F, Droz-Perroteau C, et al. Outcomes in patients after Myocardial Infarction similar to those of the PEGASUS-TIMI 54 trial: a cohort study in the French national claims database. Br J Clin Pharmacol. 2017;83:2056\u201365. https:\/\/doi.org\/10.1111\/bcp.13291.","journal-title":"Br J Clin Pharmacol"},{"key":"2101_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.11.037","volume":"281","author":"P Blin","year":"2019","unstructured":"Blin P, Dureau-Pournin C, Benichou J, Bonello L, Dallongeville J, Danchin N, et al. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): one-year real-world effectiveness and safety cohort study in the French nationwide claims database. Atherosclerosis. 2019;281:98\u2013106. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.037.","journal-title":"Atherosclerosis"},{"key":"2101_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/cpt.1318","volume":"105","author":"P Blin","year":"2019","unstructured":"Blin P, Dureau-Pournin C, Cottin Y, B\u00e9nichou J, Mismetti P, Abouelfath A, et al. Comparative effectiveness and safety of Standard or reduced dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation. Clin Pharmacol Ther. 2019;105:1439\u201355. https:\/\/doi.org\/10.1002\/cpt.1318.","journal-title":"Clin Pharmacol Ther"},{"key":"2101_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/europace\/euz285","volume":"22","author":"L Fauchier","year":"2020","unstructured":"Fauchier L, Blin P, Sacher F, Dureau-Pournin C, Bernard M-A, Lassalle R, et al. Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study. Europace. 2020;22:205\u201315. https:\/\/doi.org\/10.1093\/europace\/euz285.","journal-title":"Europace"},{"key":"2101_CR30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/fcp.12143","volume":"29","author":"J Bezin","year":"2015","unstructured":"Bezin J, Girodet P-O, Rambelomanana S, Touya M, Ferreira P, Gilleron V, et al. Choice of ICD-10 codes for the identification of acute coronary syndrome in the French hospitalization database. Fundam Clin Pharmacol. 2015;29:586\u201391. https:\/\/doi.org\/10.1111\/fcp.12143.","journal-title":"Fundam Clin Pharmacol"},{"key":"2101_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000438859","volume":"74","author":"M Giroud","year":"2015","unstructured":"Giroud M, Hommel M, Benzenine E, Fauconnier J, B\u00e9jot Y, Quantin C, et al. Positive predictive value of French hospitalization Discharge codes for Stroke and transient ischemic Attack. Eur Neurol. 2015;74:92\u20139. https:\/\/doi.org\/10.1159\/000438859.","journal-title":"Eur Neurol"},{"key":"2101_CR32","doi-asserted-by":"publisher","unstructured":"Bosco-L\u00e9vy P, Duret S, Picard F, Dos Santos P, Puymirat E, Gilleron V, Blin P, Chatellier G, Looten V, Moore N. Diagnostic accuracy of the International Classification of Diseases, Tenth Revision, codes of heart failure in an administrative database. Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):194\u2013200. https:\/\/doi.org\/10.1002\/pds.4690.","DOI":"10.1002\/pds.4690"},{"key":"2101_CR33","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/s0140-6736(99)04021-0","volume":"353","author":"H Tunstall-Pedoe","year":"1999","unstructured":"Tunstall-Pedoe H, Kuulasmaa K, M\u00e4h\u00f6nen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary Heart Disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in Cardiovascular Disease. Lancet. 1999;353:1547\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(99)04021-0.","journal-title":"Lancet"},{"key":"2101_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","volume":"20","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of Cardiovascular Disease prevalence in adults with type 2 Diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154. https:\/\/doi.org\/10.1186\/s12933-021-01344-0.","journal-title":"Cardiovasc Diabetol"},{"key":"2101_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1253\/circj.67.40","volume":"67","author":"N Tanabe","year":"2003","unstructured":"Tanabe N, Saito R, Sato T, Hayashi S, Toyoshima H, Seki N, et al. Event rates of acute Myocardial Infarction and coronary deaths in Niigata and Nagaoka cities in Japan. Circ J. 2003;67:40\u20135. https:\/\/doi.org\/10.1253\/circj.67.40.","journal-title":"Circ J"},{"key":"2101_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s1388-9842(00)00141-0","volume":"3","author":"S Stewart","year":"2001","unstructured":"Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More malignant than cancer? Five-year survival following a first admission for Heart Failure. Eur J Heart Fail. 2001;3:315\u201322. https:\/\/doi.org\/10.1016\/s1388-9842(00)00141-0.","journal-title":"Eur J Heart Fail"},{"key":"2101_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1479164112471064","volume":"10","author":"RM Cubbon","year":"2013","unstructured":"Cubbon RM, Adams B, Rajwani A, Mercer BN, Patel PA, Gherardi G, et al. Diabetes Mellitus is associated with adverse prognosis in chronic Heart Failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res. 2013;10:330\u20136. https:\/\/doi.org\/10.1177\/1479164112471064.","journal-title":"Diab Vasc Dis Res"},{"key":"2101_CR38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1089\/dia.2016.0132","volume":"18","author":"J Zhu","year":"2016","unstructured":"Zhu J, Kahn P, Knudsen J, Mehta SN, Gabbay RA. Predictive model for estimating the cost of Incident Diabetes Complications. Diabetes Technol Ther. 2016;18:625\u201334. https:\/\/doi.org\/10.1089\/dia.2016.0132.","journal-title":"Diabetes Technol Ther"},{"key":"2101_CR39","unstructured":"Robert J, Roudier C, Poutignat N, Fagt-Campana A, Weil A, Rudnichi A et al. Prise en charge des personnes diab\u00e9tiques de type 2 en France en 2007 et tendances par rapport \u00e0 2001. BEH 2009:455\u201360."},{"key":"2101_CR40","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/dom.14854","volume":"25","author":"AM Fawzy","year":"2023","unstructured":"Fawzy AM, Rivera-Caravaca JM, Underhill P, Fauchier L, Lip GYH. Incident Heart Failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with Diabetes: insights from a global federated electronic medical record database. Diabetes Obes Metab. 2023;25:602\u201310. https:\/\/doi.org\/10.1111\/dom.14854.","journal-title":"Diabetes Obes Metab"},{"key":"2101_CR41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/bmjqs-2018-008039","volume":"28","author":"S Haviari","year":"2019","unstructured":"Haviari S, Chollet F, Polazzi S, Payet C, Beauveil A, Colin C, et al. Effect of data validation audit on hospital mortality ranking and pay for performance. BMJ Qual Saf. 2019;28:459\u201367. https:\/\/doi.org\/10.1136\/bmjqs-2018-008039.","journal-title":"BMJ Qual Saf"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-02101-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02101-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T12:02:37Z","timestamp":1704801757000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-02101-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2101"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-02101-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3407181\/v1","asserted-by":"object"}]},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SNDS is a pseudonymized database and no individual patient consent was required. The study complied with all regulations including GDPR. It received a positive approval from the CEREES (Expert Committee on Health Research, Studies and Evaluations) and the authorization from the CNIL (Commission Nationale de l\u2019Informatique et des Libert\u00e9s), the French data protection authority.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript contains no individual data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PB, EG, DS, CaDP, MAB, RL, NM, CeDP are employed of the Bordeaux PharmacoEpi and do not benefit personally from this funding, except some of their salary during the study period, FTD and SB are employed of AstraZeneca, MJ, PJ and PZ are clinician experts and received fees for their participation to the scientific committee of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}